10x Genomics, Inc. (TXG) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
10x Genomics, Inc. (TXG) Earnings Overview
As of November 8, 2026, 10x Genomics, Inc. (TXG) reported trailing twelve-month net income of -$75M, reflecting +77.0% year-over-year growth. The company earned $-0.58 per diluted share over the past four quarters, with a net profit margin of -6.8%.
Looking at the long-term picture, TXG's historical earnings data spans multiple years. The company achieved its highest annual net income of -$19M in fiscal 2017.
10x Genomics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PACB (-$131M net income, -341.5% margin), ILMN ($825M net income, 19.6% margin), BRKR (-$71M net income, -0.3% margin), TXG has outperformed on profitability metrics. Compare TXG vs PACB →
TXG Earnings vs Peers
Earnings metrics vs comparable public companies
TXG Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$44M | +76.2% | -$111M | $-0.35 | -6.8% | -17.2% |
| 2024 | -$183M | +28.4% | -$195M | $-1.52 | -29.9% | -31.9% |
| 2023 | -$255M | -53.7% | -$265M | $-2.18 | -41.2% | -42.9% |
| 2022 | -$166M | -185.1% | -$168M | $-1.46 | -32.1% | -32.5% |
| 2021 | -$58M | +89.3% | -$53M | $-0.53 | -11.9% | -10.8% |
| 2020 | -$543M | -1636.7% | -$85M | $-5.37 | -181.6% | -28.6% |
| 2019 | -$31M | +72.2% | -$29M | $-0.80 | -12.7% | -11.8% |
| 2018 | -$112M | -499.5% | -$111M | $-8.40 | -76.9% | -75.7% |
| 2017 | -$19M | - | -$18M | $-1.62 | -26.4% | -25.8% |
Download Data
Export TXG earnings history in CSV or JSON format
Free sign-in required to download data
TXG Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TXG — Frequently Asked Questions
Quick answers to the most common questions about buying TXG stock.
What is TXG earnings per share (EPS)?
TXG trailing twelve-month (TTM) diluted EPS is $-0.58, reflecting +77.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is 10x Genomics, Inc.'s net income?
10x Genomics, Inc. (TXG) trailing twelve-month net income is $-75M as of 2025. Earnings grew +77.0% year-over-year.
Is TXG profitable?
TXG is not currently profitable on a TTM basis, reporting a net loss of $-75M. Net margin is -6.8%. Investors should monitor for a return to profitability.
What is TXG's earnings growth rate?
TXG compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are TXG's profit margins?
10x Genomics, Inc. net profit margin is -6.8%, operating margin is -17.2%, and gross margin is +69.1%. Below-average margins reflect competitive or cost pressures. Return on Equity is -5.8%.
Is TXG growing earnings?
Yes, TXG earnings are accelerating — EPS growth of +77.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-75M. Earnings momentum is strengthening.
What was TXG's best earnings year?
10x Genomics, Inc.'s highest annual net income on record is $-19M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were TXG's earnings last quarter?
TXG's most recent reported quarter was Q2 2026. Net income was $-18M with diluted EPS of $-0.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.